Alx Oncology Holdings (ALXO) EBT (2019 - 2026)
Alx Oncology Holdings (ALXO) reported EBT of -$21.6 million for Q1 2026, up 29.68% on a YoY basis from -$16.7 million in Q1 2025, and up 6.3% sequentially from -$23.1 million in Q4 2025.
Alx Oncology Holdings (ALXO) EBT (2019 - 2026) Analysis & Trends
Alx Oncology Holdings (ALXO) has 8 years of EBT data on file, last reported at -$21.6 million in Q1 2026.
- For the quarter ending Q1 2026, EBT rose 29.68% year-over-year to -$21.6 million; the trailing twelve-month figure through Mar 2026 stood at -$96.0 million (up 27.86% YoY), and the FY2025 full-year result was -$497000.0, up 99.63% from the prior year.
- EBT rose to -$21.6 million in Q1 2026, from -$23.1 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$21.6 million in Q1 2026 to a low of -$51.0 million in Q3 2023.
- A 5-year average of -$32.9 million and a median of -$30.7 million in 2025 frame the typical range for EBT.
- Across the five-year window, EBT slumped 1555.03% in 2022 and soared 39.77% in 2024, its largest moves.
- Tracing ALXO's EBT over 5 years: stood at -$30.6 million in 2022, then tumbled by 49.01% to -$45.7 million in 2023, then soared by 35.36% to -$29.5 million in 2024, then climbed by 21.83% to -$23.1 million in 2025, then increased by 6.3% to -$21.6 million in 2026.
- Business Quant data shows ALXO's EBT at -$21.6 million in Q1 2026, -$23.1 million in Q4 2025, and -$22.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 259.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.49 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Alx Oncology Holdings | 211.24 Mn | 211.24 Mn | - | -21.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.62 Mn |
| Dec 31, 2025 | -23.07 Mn |
| Sep 30, 2025 | -22.14 Mn |
| Jun 30, 2025 | -29.13 Mn |
| Mar 31, 2025 | -30.74 Mn |
| Dec 31, 2024 | -29.52 Mn |
| Sep 30, 2024 | -30.71 Mn |
| Jun 30, 2024 | -42.06 Mn |
| Mar 31, 2024 | -38.42 Mn |
| Dec 31, 2023 | -45.66 Mn |
| Sep 30, 2023 | -50.99 Mn |
| Jun 30, 2023 | -37.37 Mn |
| Mar 31, 2023 | -31.83 Mn |
| Dec 31, 2022 | -30.64 Mn |
| Sep 30, 2022 | -35.31 Mn |
| Jun 30, 2022 | -34.44 Mn |
| Mar 31, 2022 | -25.52 Mn |
| Dec 31, 2021 | 2.11 Mn |
| Sep 30, 2021 | -24.57 Mn |
| Jun 30, 2021 | -16.27 Mn |